Translation of the results obtained into clinical trials using a fully humanized antibody CD40 agonist in combination with chemotherapy in patients with advanced stage pancreatic cancer achieved partial response and improved patient survival [110]. This evidence concerns the gene CD40 and pancreatic neoplasm.